OBJECTIVES: Single nucleotide allelic variants in the promoter region of the chromosome 15 alpha-7 acetylcholine nicotinic receptor gene (CHRNA7) are associated with both schizophrenia and the P50 auditory evoked potential sensory gating deficit. The purpose of this study was to determine if CHRNA7 promoter allelic variants are also associated with abnormal P50 ratios in persons with schizoaffective disorder, bipolar type. METHODS: P50 auditory evoked potentials were recorded in a paired stimulus paradigm in 17 subjects with schizoaffective disorder, bipolar type. The P50 test to conditioning ratio was used as the measure of sensory gating. Mutation screening of the CHRNA7 promoter region was performed on the subjects' DNA samples. Comparisons to previously obtained data from persons with schizophrenia and controls were made. RESULTS: Subjects with schizophrenia, regardless of allele status, had an abnormal mean P50 ratio. Subjects with schizoaffective disorder, bipolar type and a variant allele had an abnormal mean P50 ratio, whereas those schizoaffective subjects with the common alleles had a normal mean P50 ratio. Normal control subjects had a normal mean ratio, but controls with variant alleles had higher P50 ratios. CONCLUSIONS: In persons with bipolar type schizoaffective disorder, CHRNA7 promoter region allelic variants are linked to the capacity to inhibit the P50 auditory evoked potential and thus are associated with a type of illness genetically and biologically more similar to schizophrenia.
OBJECTIVES: Single nucleotide allelic variants in the promoter region of the chromosome 15 alpha-7 acetylcholine nicotinic receptor gene (CHRNA7) are associated with both schizophrenia and the P50 auditory evoked potential sensory gating deficit. The purpose of this study was to determine if CHRNA7 promoter allelic variants are also associated with abnormal P50 ratios in persons with schizoaffective disorder, bipolar type. METHODS:P50 auditory evoked potentials were recorded in a paired stimulus paradigm in 17 subjects with schizoaffective disorder, bipolar type. The P50 test to conditioning ratio was used as the measure of sensory gating. Mutation screening of the CHRNA7 promoter region was performed on the subjects' DNA samples. Comparisons to previously obtained data from persons with schizophrenia and controls were made. RESULTS: Subjects with schizophrenia, regardless of allele status, had an abnormal mean P50 ratio. Subjects with schizoaffective disorder, bipolar type and a variant allele had an abnormal mean P50 ratio, whereas those schizoaffective subjects with the common alleles had a normal mean P50 ratio. Normal control subjects had a normal mean ratio, but controls with variant alleles had higher P50 ratios. CONCLUSIONS: In persons with bipolar type schizoaffective disorder, CHRNA7 promoter region allelic variants are linked to the capacity to inhibit the P50 auditory evoked potential and thus are associated with a type of illness genetically and biologically more similar to schizophrenia.
Authors: L Curtis; J L Blouin; U Radhakrishna; C Gehrig; V K Lasseter; P Wolyniec; G Nestadt; B Dombroski; H H Kazazian; A E Pulver; D Housman; D Bertrand; S E Antonarakis Journal: Am J Med Genet Date: 1999-04-16
Authors: H J Edenberg; T Foroud; P M Conneally; J J Sorbel; K Carr; C Crose; C Willig; J Zhao; M Miller; E Bowman; A Mayeda; N L Rau; C Smiley; J P Rice; A Goate; T Reich; O C Stine; F McMahon; J R DePaulo; D Meyers; S D Detera-Wadleigh; L R Goldin; E S Gershon; M C Blehar; J I Nurnberger Journal: Am J Med Genet Date: 1997-05-31
Authors: Vincenzo De Luca; Haoran Wang; Alessio Squassina; Greg W H Wong; John Yeomans; James L Kennedy Journal: Neuropsychobiology Date: 2004 Impact factor: 2.328
Authors: E Houy; G Raux; F Thibaut; A Belmont; C Demily; G Allio; S Haouzir; G Fouldrin; M Petit; T Frebourg; D Campion Journal: Mol Psychiatry Date: 2004-03 Impact factor: 15.992
Authors: C A Kaufmann; B Suarez; D Malaspina; J Pepple; D Svrakic; P D Markel; J Meyer; C T Zambuto; K Schmitt; T C Matise; J M Harkavy Friedman; C Hampe; H Lee; D Shore; D Wynne; S V Faraone; M T Tsuang; C R Cloninger Journal: Am J Med Genet Date: 1998-07-10
Authors: Melissa L Sinkus; Sharon Graw; Robert Freedman; Randal G Ross; Henry A Lester; Sherry Leonard Journal: Neuropharmacology Date: 2015-02-19 Impact factor: 5.250
Authors: Jean-Baptiste Le Pichon; Shihui Yu; Nataliya Kibiryeva; William D Graf; Douglas C Bittel Journal: Eur J Hum Genet Date: 2013-01-30 Impact factor: 4.246
Authors: Ardesheer Talati; Yuanyuan Bao; Jake Kaufman; Ling Shen; Catherine A Schaefer; Alan S Brown Journal: Am J Psychiatry Date: 2013-10 Impact factor: 18.112
Authors: Jordan P Hamm; Lauren E Ethridge; Nashaat N Boutros; Matcheri S Keshavan; John A Sweeney; Godfrey D Pearlson; Carol A Tamminga; Brett A Clementz Journal: Psychophysiology Date: 2014-02-20 Impact factor: 4.016
Authors: Frank Bellivier; Pierre Alexis Geoffroy; Jan Scott; Franck Schurhoff; Marion Leboyer; Bruno Etain Journal: Front Biosci (Elite Ed) Date: 2013-06-01
Authors: Martin Reite; Erik Reite; Dan Collins; Peter Teale; Donald C Rojas; Elliot Sandberg Journal: BMC Psychiatry Date: 2010-10-11 Impact factor: 3.630